Signet Ring Cell Carcinoma of the Appendix: Understanding Your Pathology Report

Section Editor: David Driman MBChB FRCPC
November 17, 2026


Print this article

Signet ring cell carcinoma of the appendix is a rare, fast-growing cancer that starts in the lining of the appendix. It is named for its cancer cells, which are so full of mucin that the nucleus is pushed against the edge of the cell. Under the microscope, each cell looks like a ring with a stone set in it. Your report may also call it signet ring cell adenocarcinoma or signet-ring cell carcinoma.

This article explains how signet ring cell carcinoma of the appendix is diagnosed and how it differs from other appendix cancers. It also explains what the stage and other findings in your pathology report mean.

What makes a cancer a signet ring cell carcinoma?

Many appendix cancers contain some signet ring cells. The name signet ring cell carcinoma is used only when signet ring cells make up more than half of the cancer cells. When they make up less than half, the report usually names the main type of cancer and adds that signet ring cells are present.

Signet ring cells tend to grow as single cells or loose clusters rather than forming glands. This pattern lets them spread through the appendix wall and across the lining of the abdomen. For this reason, signet ring cell carcinoma is usually found at a later stage than other appendix cancers.

Who gets signet ring cell carcinoma of the appendix?

Signet ring cell carcinoma makes up about 7 in every 100 cancers of the appendix. In a large United States registry study, the median age at diagnosis was 56 years. Almost two-thirds of the people affected were women. The cause is not known, and most cases are not inherited.

What are the symptoms of signet ring cell carcinoma of the appendix?

Signet ring cell carcinoma of the appendix often causes symptoms of acute appendicitis, including pain in the lower right abdomen, fever, and nausea. In many people, the cancer has already spread when it is found, which can cause:

  • Swelling of the abdomen. Cancer on the lining of the abdomen can cause fluid to build up.
  • An ovarian mass in women. The ovaries are a common site of spread and are sometimes where the cancer is first found.
  • Weight loss and tiredness. These general symptoms are common with advanced disease.

How is the diagnosis made?

The diagnosis of signet ring cell carcinoma of the appendix is usually made after the appendix is removed, either in an appendectomy or as part of a larger operation. It may also be made from a biopsy of the lining of the abdomen, the omentum, or an ovary. A pathologist examines the tissue under the microscope.

The pathologist confirms that the cells are true signet ring cells. Dying cells and immune cells floating in mucin can look similar but are not cancer. A stain for mucin, such as mucicarmine, can highlight the mucin inside the cancer cells.

A CT scan of the chest, abdomen, and pelvis is used to look for spread. Because signet ring cell carcinoma can also start in the stomach or breast, your doctor may recommend an upper endoscopy or a breast examination. Your doctor may also order blood tests for tumor markers, such as CEA and CA19-9.

Immunohistochemistry

Immunohistochemistry helps the pathologist confirm where a signet ring cell carcinoma started. This matters because signet ring cell carcinomas from other organs can spread to the appendix and look the same. Stains you may see in your report include:

  • CK20 and CDX2. CK20 and CDX2 are made by cells lining the bowel. A positive result supports a cancer that started in the appendix or bowel.
  • Estrogen receptor and GATA3. Many breast cancers make these proteins. They are usually negative in signet ring cell carcinoma of the appendix. A positive result raises the possibility of spread from a lobular breast cancer.
  • Synaptophysin and chromogranin. Synaptophysin and chromogranin mark neuroendocrine cells. Scattered positive cells may suggest a high-grade goblet cell adenocarcinoma rather than a pure signet ring cell carcinoma.

No single stain can separate a cancer from the appendix from one that started in the stomach. When there is doubt, the pathologist combines the stains with the location of the tumor, imaging, and the results of an upper endoscopy.

Signet ring cell carcinoma or goblet cell adenocarcinoma?

A high-grade goblet cell adenocarcinoma can contain many cells that look like signet ring cells. The two cancers are separated by looking for areas of the classic, low-grade goblet cell pattern of small round clusters. When those areas are present anywhere in the tumor, the diagnosis is goblet cell adenocarcinoma, even if most of the tumor looks like signet ring cell carcinoma.

This distinction matters because the two cancers are staged the same way but have different outlooks. In a large registry study, people with signet ring cell carcinoma had shorter survival than people with goblet cell tumors of the same stage.

Histologic grade

Signet ring cell carcinoma of the appendix is high grade by convention. Grade describes how abnormal the cancer cells look and how they grow. The College of American Pathologists (CAP) appendix protocol, version 5.1.0.0 (2022), assigns signet ring cell carcinoma to grade 3 (G3). Grade helps predict behavior and guides treatment decisions. In this cancer, the high grade also places spread to the lining of the abdomen in stage IVB rather than IVA.

Tumor extension

Signet ring cell carcinoma of the appendix often spreads widely through the wall without forming a distinct mass. The pathologist reports the deepest layer the cancer cells have reached: the submucosa, the muscularis propria, the subserosa, or the outer covering called the serosa. Spread into the mesoappendix, the fatty tissue attached to the appendix, is also reported. The deepest layer reached sets the tumor stage (pT).

Perineural invasion

Perineural invasion means signet ring cancer cells were seen surrounding or following a nerve. The cells can travel along nerves well beyond the visible tumor. The report lists perineural invasion as “not identified,” “present,” or “cannot be determined” for the specimen.

Lymphovascular invasion

Lymphovascular invasion means signet ring cancer cells were seen inside a small blood vessel or lymphatic channel. From these channels, cancer cells can reach lymph nodes and distant organs. The report lists lymphovascular invasion as “not identified,” “present,” or “cannot be determined” for the specimen.

Surgical margins

A margin is a cut edge of the tissue removed to treat the signet ring cell carcinoma. The proximal margin is where the appendix was divided from the large bowel, and the mesenteric margin is the cut edge of the mesoappendix. After a right hemicolectomy, the two ends of the bowel are also examined. Single signet ring cells can be hard to see, so the pathologist may use stains to carefully check the margins.

Under the CAP appendix protocol, version 5.1.0.0 (2022), margins are described in two ways:

  • Negative margin. No cancer cells are seen at any cut edge. The report may add the distance to the mesenteric margin.
  • Positive margin. Cancer cells reach a cut edge, and the report names which one. Further surgery or other treatment may be considered.

Lymph nodes

Lymph nodes are small immune organs that trap cells and fluid draining from tissues. Signet ring cell carcinoma of the appendix often spreads to the lymph nodes along the right colon. A right hemicolectomy removes these nodes, and pathologists usually examine 12 or more.

The report lists how many lymph nodes were examined and how many contain cancer. Signet ring cells in a lymph node can be scattered and few, so pathologists may use stains to find them. The report may also describe tumor deposits in the surrounding fat or extranodal extension, meaning cancer growing through the capsule of a node.

Biomarker and molecular testing

Biomarker tests for signet ring cell carcinoma of the appendix look for uncommon changes that could open specific treatment options. They are usually done when the cancer has spread.

Mismatch repair (MMR) and microsatellite instability (MSI)

Mismatch repair proteins repair mistakes in copied DNA. The proteins MLH1, PMS2, MSH2, and MSH6 are tested by immunohistochemistry, or microsatellite instability is tested in the tumor DNA.

  • Proficient (pMMR), intact, retained, or microsatellite stable (MSS). All four proteins are present. This is the expected result.
  • Deficient (dMMR), loss of expression, or MSI-high. One or more proteins are absent. Pembrolizumab is approved by the FDA (2017) and Health Canada for unresectable or metastatic solid tumors with this result that have grown after earlier treatment. Genetic counseling for Lynch syndrome may also be offered.

Next-generation sequencing

Next-generation sequencing (NGS) examines many genes at once. It can find rare changes linked to treatments approved for any solid tumor.

  • No targetable change. None of the changes linked to an approved drug was found. This is the most common result.
  • BRAF V600E. Dabrafenib with trametinib received accelerated approval from the FDA in 2022 for solid tumors with this change that have grown after earlier treatment.
  • NTRK fusion. Larotrectinib and entrectinib are authorized by Health Canada, with conditions, for solid tumors with an NTRK fusion.
  • TMB-high. Pembrolizumab received accelerated approval from the FDA in 2020 for TMB-high solid tumors that have grown after earlier treatment.

More information on each test is in our Biomarkers and Genetic Testing section.

Pathologic stage (pTNM)

Signet ring cell carcinoma of the appendix is staged using the American Joint Committee on Cancer (AJCC) appendix carcinoma system, Version 9 (2023). The pathologist provides pT and pN, and imaging and biopsies assess distant spread. Read our article on TNM staging to see how the parts fit together.

Tumor stage (pT)

  • pT1. Cancer cells have reached the submucosa.
  • pT2. Cancer cells have reached the muscularis propria.
  • pT3. Cancer cells have passed through the muscle into the subserosa or mesoappendix.
  • pT4a. Cancer cells have reached the outer surface of the appendix through the serosa.
  • pT4b. Cancer has grown into a neighboring organ or structure.
  • pTX. The extent of the cancer cannot be assessed.

Nodal stage (pN)

  • pN0. No lymph nodes contain cancer.
  • pN1a. One lymph node contains cancer.
  • pN1b. Two or three lymph nodes contain cancer.
  • pN1c. Only tumor deposits are present.
  • pN2. Four or more lymph nodes contain cancer.
  • pNX. Lymph nodes were not available for examination.

Spread to the lining of the abdomen (M1b) is stage IVB for signet ring cell carcinoma, because the cancer is grade 3. Spread beyond the lining, such as to the liver or lungs (M1c), is stage IVC.

What is the prognosis?

The prognosis for signet ring cell carcinoma of the appendix is generally poor, because most cancers have spread by the time they are found. In the largest registry study, about 6 in 10 people had distant spread at diagnosis. The median survival was about 26 months. About 18 in 100 people were alive and free of death from the cancer 5 years after diagnosis, and about 82 in 100 were not.

The outlook is better when the cancer is small and found early. In the same study, people with tumors smaller than 2 cm had a 5-year cancer-specific survival of about 50%. People who had surgery also did better than those who did not. Features associated with a worse outcome include:

  • Spread to the lining of the abdomen or ovaries. This is the most common pattern of spread and the hardest to control.
  • Spread to distant organs. Spread beyond the abdomen carries the least favorable outlook.
  • Lymph node spread. Cancer in lymph nodes raises the stage.
  • Larger tumor size. Tumors 2 cm or larger had poorer survival.
  • Positive margin. Cancer at a cut edge raises the chance of the cancer returning.

What happens after the diagnosis?

After signet ring cell carcinoma of the appendix is confirmed, your care team will review the imaging, the stage, and whether the cancer has spread. A surgeon and a medical oncologist usually plan your care, often at a specialist center.

  • Right hemicolectomy. When the cancer has not spread beyond the appendix and nearby tissue, this operation removes the right colon and its lymph nodes.
  • Removal of the ovaries. In women, the team may discuss removing the ovaries, because they are a common site of spread.
  • Chemotherapy. Chemotherapy similar to that used for colon cancer is often recommended, both after surgery and when the cancer has spread.
  • Cytoreductive surgery and HIPEC. For spread to the lining of the abdomen, this approach is considered only in carefully selected people. Results are less favorable when signet ring cells are present than for other appendix cancers.
  • Clinical trials. Because this cancer is rare and hard to treat, your oncologist can tell you whether a trial is available.

Questions to ask your doctor

  • What percentage of the cancer cells were signet ring cells?
  • How sure is the pathologist that the cancer started in the appendix and not the stomach or breast?
  • Could this be a goblet cell adenocarcinoma instead?
  • How deeply did the cancer grow, and did it reach the serosa?
  • Were the margins negative?
  • How many lymph nodes contained cancer?
  • Did imaging or surgery show cancer on the lining of my abdomen or on my ovaries?
  • What is my stage?
  • Do I need an upper endoscopy or other tests to rule out cancer elsewhere?
  • Which biomarker tests were done on my cancer, and what were the results?
  • What treatment do you recommend, and what is its goal?
  • Would cytoreductive surgery with HIPEC help in my situation?
  • Are there clinical trials I could join?

Related articles on MyPathologyReport.com

A+ A A-
Was this article helpful?